Iovance: The Company Makes It Hard To Estimate Revenue Growth
Source: SeekingAlpha
2025-03-18 12:02:56 ET
Summary
- Iovance reported Q4'24 revenues of $25M from Proleukin, a 51% increase from the prior quarter, but Amtagvi revenues of 48.7M, were up just 16% from the prior quarter.
- Proleukin revenues could be a leading indicator for Amtagvi revenues, but the company also supplied a new distributor in Q4'24, making it hard to judge Q1'25 Amtagvi growth.
- Obsidian Therapeutics represents a relevant competitor with a cell therapy called OBX-115, that has potential advantages over lifileucel, although IOVA has its own next-gen therapies in development.
Read the full article on Seeking Alpha
For further details see:
Iovance: The Company Makes It Hard To Estimate Revenue Growth
Immatics N.V.
NASDAQ: IMTX
IMTX Trading
-0.61% G/L:
$11.37 Last:
87,110 Volume:
$11.48 Open:
IMTX Latest News
May 30, 2026 08:00:00 am
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
May 12, 2026 07:00:00 am
Immatics Announces First Quarter 2026 Financial Results and Business Update
IMTX Stock Data
$1,341,978,928
63,814,383
N/A
32
N/A
Biotechnology & Life Sciences
Healthcare
DE
Tbingen
